Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab with HSCT-supported Chemotherapy in ES-SCLC
NCT06597513Phase 2Not yet recruiting
- Start
- Dec 2024
- Primary completion
- Dec 2025
- Modality
- Immune Checkpoint Inhibitors
01
Overview
Phase 2, open-label, single-arm trial of adebrelimab in small cell lung cancer (SCLC). Primary endpoint: Number of Participants with Treatment-Related Adverse Events as Assessed by CTCAE v5.0. Planned start Dec 2024; status: not yet recruiting.
02
Drugs
adebrelimab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT06597513.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06597513.